RecruitingPhase 3NCT04382846
Novel Regimens in COVID-19 Treatment
Nitazoxanide in Treatment of COVID-19
Sponsor
Tanta University
Enrollment
160 participants
Start Date
May 8, 2020
Study Type
INTERVENTIONAL
Conditions
Summary
Nitazoxanide has been shown to have a clinical efficacy against severe acute respiratory syndrome coronavirus 2; ivermectin has also demonstrated a remarkable experimental efficacy with a potential to be used for Coronavirus disease 2019.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- Patients with COVID-19 infection
Exclusion Criteria1
- Allergy or contraindication to the drugs.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNitazoxanide
Nitazoxanide
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04382846
Related Trials
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
NCT045795881 location
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
NCT0491026965 locations
Risk Factors, Clinical Characteristics and Outcomes of Acute Infection With Coronavirus 2019 (COVID-19) In Children
NCT043713151 location
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
NCT044481451 location
Prospective Clinical Evaluation of the BioFire Emerging Coronavirus Panel for the Detection of COVID-19 and Other Coronaviruses
NCT072210976 locations